J. Fredrickson

发表

18F-Fluoroestradiol PET/CT Measurement of Estrogen Receptor Suppression during a Phase I Trial of the Novel Estrogen Receptor-Targeted Therapeutic GDC-0810: Using an Imaging Biomarker to Guide Drug Dosage in Subsequent Trials

E. Winer, J. Baselga, A. Bardia, 2016, Clinical Cancer Research.

First-in-Human Phase I Study of Pictilisib (GDC-0941), a Potent Pan–Class I Phosphatidylinositol-3-Kinase (PI3K) Inhibitor, in Patients with Advanced Solid Tumors

J. Ware, J. Spoerke, P. Workman, 2014, Clinical Cancer Research.

Selective modulation of PPARγ activity can lower plasma glucose without typical thiazolidinedione side-effects in patients with Type 2 diabetes.

A. Depaoli, F. Dunn, J. Fredrickson, 2011, Journal of diabetes and its complications.

Splenic metabolic activity predicts risk of future cardiovascular events: demonstration of a cardiosplenic axis in humans.

J. Min, Z. Fayad, K. Nasir, 2015, JACC. Cardiovascular imaging.

Phase I study of the anti-α5β1 monoclonal antibody MINT1526A with or without bevacizumab in patients with advanced solid tumors

P. Hegde, K. Wong, L. Rosen, 2018, Cancer Chemotherapy and Pharmacology.

Clinical translation of ferumoxytol‐based vessel size imaging (VSI): Feasibility in a phase I oncology clinical trial population

A. D. de Crespigny, R. Carano, N. Serkova, 2017, Magnetic resonance in medicine.

FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open‐Label Study of Atezolizumab in PD‐L1–Selected Patients With NSCLC

S. Gettinger, N. Rizvi, J. Chaft, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A first-in-human phase I study to evaluate GDC-0980, an oral PI3K/mTOR inhibitor, administered QD in patients with advanced solid tumors.

J. Ware, J. Bendell, H. Burris, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

FDG-PET imaging for oxidized LDL in stable atherosclerotic disease: a phase II study of safety, tolerability, and anti-inflammatory activity.

N. van Bruggen, Z. Fayad, D. Duprez, 2015, JACC. Cardiovascular imaging.

The oral selective estrogen receptor degrader GDC-0810 (ARN-810) in postmenopausal women with hormone receptor-positive HER2-negative (HR + /HER2 −) advanced/metastatic breast cancer

Carlos L. Arteaga, H. Linden, A. Bardia, 2022, Breast Cancer Research and Treatment.

Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors

M. Zauderer, R. Yeh, J. Ware, 2016, Clinical Cancer Research.

Treatment with a human recombinant monoclonal IgG antibody against oxidized LDL in atherosclerosis-prone pigs reduces cathepsin S in coronary lesions.

E. Falk, S. Moestrup, Esad Vucic, 2016, International journal of cardiology.

Quantitative Model of the Relationship Between Dipeptidyl Peptidase‐4 (DPP‐4) Inhibition and Response: Meta‐Analysis of Alogliptin, Saxagliptin, Sitagliptin, and Vildagliptin Efficacy Results

J. Gibbs, Brian G. Smith, M. Gibbs, 2012, Journal of clinical pharmacology.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational New Drugs.

Fibroblast growth factor receptor 1/Klothoβ agonist BFKB8488A improves lipids and liver health markers in patients with diabetes or NAFLD: A phase 1b randomized trial

N. Lewin-Koh, J. Fredrickson, A. Dash, 2022, Hepatology.

Meta-Analysis of 49 Roche Oncology Trials Comparing Blinded Independent Central Review (BICR) and Local Evaluation to Assess the Value of BICR.

Alexander Hillebrecht, J. Fredrickson, M. Hilton, 2023, The oncologist.

Abstract PD7-05: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-9545, in postmenopausal women with estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer

E. Winer, S. Loi, A. Bardia, 2020, Poster Spotlight Session Abstracts.

Abstract PD5-10: A first-in-human phase I study to evaluate the oral selective estrogen receptor degrader (SERD), GDC-0927, in postmenopausal women with estrogen receptor positive (ER+) HER2-negative metastatic breast cancer (BC)

A. Bardia, J. Spoerke, J. Giltnane, 2018 .

Tumor Segmentation and Feature Extraction from Whole-Body FDG-PET/CT Using Cascaded 2D and 3D Convolutional Neural Networks

Thomas Bengtsson, Tina Nielsen, Skander Jemaa, 2020, Journal of Digital Imaging.

A Fully Automated Measurement of Total Metabolic Tumor Burden in Diffuse Large B-Cell Lymphoma and Follicular Lymphoma

R. Carano, T. Bengtsson, A. Coimbra, 2019, Blood.

Phase Ib study of the MEK inhibitor cobimetinib (GDC-0973) in combination with the PI3K inhibitor pictilisib (GDC-0941) in patients with advanced solid tumors

Suzanne F. Jones, C. Rudin, G. Shapiro, 2019, Investigational new drugs.

Deep Ensembles Are Robust to Occasional Catastrophic Failures of Individual DNNs for Organs Segmentations in CT Images

Y. Petrov, J. Fredrickson, R. Carano, 2023, Journal of Digital Imaging.

A phase Ib dose-escalation study of the safety, pharmacokinetics (PK), pharmacodynamics (PD), and antitumor activity of the humanized monoclonal antibody (huMAb) anti-EGFL7 (MEGF0444A) in combination with bevacizumab with or without paclitaxel in patients with advanced solid tumors.

P. Hegde, P. Munster, L. Naumovski, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Utility of FDG-PET in immunotherapy: results from a Phase II study of NSCLC patients undergoing therapy with the PD-L1 inhibitor, atezolizumab (MPDL3280A)

W. Weber, R. Hicks, J. Fredrickson, 2016 .

Metabolic tumor burden for prediction of overall survival following combined BRAF/MEK inhibition in patients with advanced BRAF mutant melanoma.

A. Ribas, I. Puzanov, A. Daud, 2014 .